What's new

China to use BioNTech vaccine as booster shot, sources say

There's a whole lot going on which unfortunately the masses are unaware of.. if you're interested, have a read of this thread.

Just read the link.

I think if this is related to spike protein...

Then it's not just mRNA vaccine problem alone, but all covid-19 vaccines are troublesome as well.

The difference is just the spike protein production, the more potent the vaccine the more spike protein and the larger the side effect from it.

But even a less potent vaccine, if injected multiple times, like the third, fourth, and so on booster it will be as dangerous as mRNA vaccine.
 
The vaccine is called the Fosun–BioNTech COVID‑19 vaccine not just "BionTech vaccine", funny how certain people who worship the US call the the Pfizer–BioNTech COVID-19 vaccine just the "Pfizer vaccine" because Pfizer is an American company but when it comes to the one co-developed and produced with the Chinese company Fosun they chose to call it the BioNTech vaccine instead of calling it the Fosun vaccine like what they do with the American one.
Exactly, additionally most Chinese have already taken SinoPharm or Sinovac Vaccine. This BioNTech vaccine will be made in China. And as stated will be a booster shot for now.
 

Chinese drug regulators completed an expert panel review of a COVID-19 mRNA vaccine co-developed by Fosun Pharma and Germany's BioNTech, and now the shot is in the administrative review stage, according to Fosun.

The Shanghai-based pharmaceutical company is sticking with its previously announced plan to start domestic trial production by the end of August, Fosun Chairman Wu Yifang said Wednesday at a shareholders meeting.

Chinese authorities plan to use the vaccine, which goes by the brand name Comirnaty, as a booster shot for people who have received inactivated-virus vaccines, people close to regulators told Caixin. The booster shot is likely to be offered free of charge.

China has administered more than 1.2 billion vaccine doses, as of July 1, according to the National Health Commission. Most people have received inactivated-virus vaccines made by Sinovac and state-owned Sinopharm Group that have demonstrated lower efficacy than mRNA vaccines.

While awaiting regulatory clearance, Fosun Pharma and BioNTech started preparations and bought equipment for their Shanghai-based joint venture. Installation of production lines in the Shanghai plant is set to be completed in August, Fosun said in June.

Fosun and BioNTech in May announced plans to set up the Shanghai facility to produce BioNTech's mRNA vaccine Comirnaty, also known as BNT162b2. The venture is part of a broader partnership formed in early 2020 to bring the vaccine to China.

Wu said the Shanghai factory will hit its annual production capacity of 1 billion doses of COVID-19 vaccine by the end of this year. With the assistance of Fosun's other facilities, monthly output can expand to 100 million to 200 million doses, Wu said.

Fosun sealed a deal to sell 10 million vaccine doses to Taiwan following months of on-again, off-again talks that finally reached a breakthrough after the island experienced a recent COVID-19 outbreak.

The University of Hong Kong is studying the effect of mixing shots of BioNTech's Comirnaty and one made by Sinovac Life Sciences. Fosun and the Chinese government are also conducting vaccine-mixing research. The currently available data suggest favorable results, Wu said.

The efficacy of the Chinese shots ranges from 50% to almost 80% in trials and real-world studies, significantly lower than the mRNA vaccines developed by Moderna and Pfizer-BioNTech. That has raised concerns they may not be effective in taming the virus's more infectious variants.

The Pfizer-BioNTech and Moderna vaccines cover all existing variants and can provide a high degree of protection, although with reduced effectiveness, said Jin Dongyan, a molecular virologist at the University of Hong Kong.


--

Read also the original story.

Caixinglobal.com is the English-language online news portal of Chinese financial and business news media group Caixin. Nikkei recently agreed with the company to exchange articles in English.

fake news!
 
Another CIA propaganda. The truth is the Fosun-BioNtech mRNA vaccine will be used as one type of booster vaccine among tens of different vaccine in China if it is gotten approved by NMPA
I think most people will not choose mRNA vaccine due to its side-effect
I personally will choose protein sub-unit based vaccine as booster vaccine.
 
Another CIA propaganda. The truth is the Fosun-BioNtech mRNA vaccine will be used as one type of booster vaccine among tens of different vaccine in China if it is gotten approved by NMPA
I think most people will not choose mRNA vaccine due to its side-effect
I personally will choose protein sub-unit based vaccine as booster vaccine.

Can't wait until it's available
 
Back
Top Bottom